- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
Approvals for four breakthrough treatments are expected in late 2022 as part of the gene therapy drug pipeline. In addition, therapies could be approved for conditions including refractory follicular lymphoma, hemophilia A, hemophilia B, diabetic peripheral neuropathy and others from now through 2025.
Our quarterly gene therapy pipeline update shares information about treatments that may come up for review and approval by the U.S. Food and Drug Administration (FDA) in the near term.
Ongoing monitoring of the gene therapy pipeline can help payors anticipate and plan for the impact of new drugs and expanded indications. We will continue to share updates to the gene therapy pipeline periodically.